Investors, Llc Medpace Net Worth

The estimated Net Worth of Investors, Llc Medpace is at least $2.58 Miliarda dollars as of 6 March 2024. Investors Medpace owns over 200,000 units of Medpace Inc stock worth over $1,583,526,167 and over the last 7 years Investors sold MEDP stock worth over $999,641,760.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Investors Medpace MEDP stock SEC Form 4 insiders trading

Investors has made over 108 trades of the Medpace Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Investors sold 200,000 units of MEDP stock worth $82,322,000 on 6 March 2024.

The largest trade Investors's ever made was selling 243,518 units of Medpace Inc stock on 27 July 2020 worth over $30,495,759. On average, Investors trades about 54,622 units every 18 days since 2017. As of 6 March 2024 Investors still owns at least 4,733,019 units of Medpace Inc stock.

You can see the complete history of Investors Medpace stock trades at the bottom of the page.

What's Investors Medpace's mailing address?

Investors's mailing address filed with the SEC is C/O MEDPACE HOLDINGS, INC., 5375 MEDPACE WAY, CINCINNATI, OH, 45227.

Insiders trading at Medpace Inc

Over the last 8 years, insiders at Medpace Inc have traded over $3,140,136,825 worth of Medpace Inc stock and bought 2,899,276 units worth $330,034,155 . The most active insiders traders include Limited Partnership Medpace..., August J. Troendle a Investors, Llc Medpace. On average, Medpace Inc executives and independent directors trade stock every 9 days with the average trade being worth of $40,224,347. The most recent stock trade was executed by Robert O. Kraft on 22 August 2024, trading 8,127 units of MEDP stock currently worth $346,373.

What does Medpace Inc do?

a therapeutically focused leader in research-based drug development, medpace builds strong strategic partnerships with select sponsors to advance the most efficient and cost-effective path to drug approval. as a full service, global clinical research organization (cro), medpace sees itself as a steward of your drug, leveraging its extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. from custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs, on six continents.

Complete history of Investors Medpace stock trades at Medpace Inc

Medpace Inc executives and stock owners

Medpace Inc executives and other stock owners filed with the SEC include:

• August Troendle,
  Chairman of the Board, President, Chief Executive Officer
• Susan Burwig,
  Executive Vice President - Operations
• Jesse Geiger,
  Chief Financial Officer, Chief Operating Officer - Laboratory Operations
• Stephen Ewald,
  General Counsel, Corporate Secretary
• Dr. August James Troendle M.D.,
  Chairman & CEO
• Susan E. Burwig,
  Exec. VP of Operations
• Jesse J. Geiger BBA, CPA,
  Pres
• Stephen P. Ewald,
  Chief Compliance Officer, Gen. Counsel & Corp. Sec.
• Brian Carley,
  Independent Director
• Robert Kraft,
  Independent Director
• Fred Davenport,
  Lead Independent Director
• Cornelius McCarthy,
  Independent Director
• Ashley Keating,
  Independent Director
• Thomas King,
  Independent Director
• Brandon Ebken,
  Chief Information Officer
• John T. Wynne,
  Sr. VP of Commercial Operations & Clinical Pharmacology Unit
• Daniel O'Leary,
  Sr. VP of Medical Department
• Weimin Gai MS,
  Sr. VP of Biometrics
• Todd Meyers,
  VP of Bus. Devel. & Marketing
• Lauren Morris,
  Associate Director of Investors Relations
• Kevin M. Brady,
  CFO & Treasurer
• Penelope J Bucknell,
  VP, Human Resources
• Bruce Brown,
  Director
• Cinven Fund (No. 1) Limited...,
  
• Limited Partnership Medpace...,
  
• Dani S. Zander,
  Director
• Investors, Llc Medpace,
  10% owner
• Tom C King,
  Director
• Kevin M. Brady,
  CFO & Treasurer